Next Article in Journal
Improving Communication between Physicians and Their Patients through Mindfulness and Compassion-Based Strategies: A Narrative Review
Previous Article in Journal
The Relationship between Mitochondrial Respiratory Chain Activities in Muscle and Metabolites in Plasma and Urine: A Retrospective Study
Previous Article in Special Issue
The Roles of Histone Demethylase Jmjd3 in Osteoblast Differentiation and Apoptosis
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
J. Clin. Med. 2017, 6(3), 32; doi:10.3390/jcm6030032

In Vitro and In Vivo Effects of Gracilaria verrucosa Extracts on Osteoclast Differentiation

Department of Pharmacy, Sunchon National University, Jeonnam, Suncheon 57922, Korea
*
Author to whom correspondence should be addressed.
Academic Editor: Hirohiko Okamura
Received: 30 December 2016 / Revised: 6 March 2017 / Accepted: 10 March 2017 / Published: 14 March 2017
(This article belongs to the Special Issue Bone Cell Biology and Transcriptional Regulation)
View Full-Text   |   Download PDF [1422 KB, uploaded 16 March 2017]   |  

Abstract

Bone remodeling, a physiological process characterized by bone formation by osteoblasts and bone resorption by osteoclasts, is important for the maintenance of healthy bone in adult humans. Osteoclasts play a critical role in bone erosion and osteoporosis and are bone-specific multinucleated cells generated through differentiation of monocyte/macrophage lineage precursors. Receptor activator of NF-κB ligand (RANKL) has been reported to induce osteoclast differentiation. In this study, we explored whether Gracilaria verrucosa extracts (GE) could affect RANKL-mediated osteoclast differentiation. GE significantly inhibited RANKL-activated osteoclast differentiation by inhibiting protein expression of c-fos and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), vital factors in RANKL-mediated osteoclastogenesis. In addition, GE attenuated ovariectomy-induced bone loss in mice. In summary, GE can prevent osteoclastogenesis and hormone-related bone loss via blockage of c-fos-NFATc1 signaling. Our results suggest that GE may have therapeutic potential in the treatment of postmenopausal osteoporosis. View Full-Text
Keywords: bone; osteoporosis; osteoclast; receptor activator of nuclear factor-κB ligand (RANKL); nuclear factor of activated T-cells; cytoplasmic 1 (NFATc1); in vivo; seaweed; Gracilaria verrucosa bone; osteoporosis; osteoclast; receptor activator of nuclear factor-κB ligand (RANKL); nuclear factor of activated T-cells; cytoplasmic 1 (NFATc1); in vivo; seaweed; Gracilaria verrucosa
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kim, K.-J.; Lee, Y.-J.; Hwang, Y.-H.; Kang, K.-Y.; Yee, S.-T.; Son, Y.-J. In Vitro and In Vivo Effects of Gracilaria verrucosa Extracts on Osteoclast Differentiation. J. Clin. Med. 2017, 6, 32.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top